Lilly Provides Update on A4 Study of Solanezumab for Preclinical Alzheimer's Disease
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
J.P. Morgan sees recent Eli Lilly (LLY) weakness as opportunity ahead of Donanemab Ph3 Data
March 9, 2023 1:01 PM ESTJ.P. Morgan reiterated an Overweight rating and a $400.00 price target on Eli Lilly and Company (NYSE: LLY) ahead of the upcoming release of the donanemab ph3 data.
Analyst Chris Schott wrote in a note, Following recent LLY weakness, we have been receiving a number of questions on the story and wanted to provide our updated thoughts on upcoming donanemab ph3 data as well as... More
